Clinical Trial Update: Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of a COVID-19 DNA vaccine (AG0302-COVID19 High-dose) has completed investigation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Lower Respiratory Infection

Drugs mentioned

• AG0302-COVID19 High-dose

Snippet

Sponsor: AnGes, Inc. | Conditions: COVID-19 Lower Respiratory Infection | Phase 1, Phase 2 | Status: COMPLETED